Literature DB >> 10640596

Vaccines, coming of age after 200 years.

P H Mäkelä1.   

Abstract

An overview on the short, only 200 years, past history and future expectations in the field of vaccines is presented. The focus is on development trends and potential rather than individual vaccines. While the first vaccines were a result of keen observation, the further development has been tightly dependent on the development of microbiology to provide both the knowledge basis and the technology for new vaccines for new purposes. The post-genomic era just starting therefore promises an exponential increase of vaccine research and new vaccines, both improved vaccines with a greater efficacy and less adverse effects to replace old ones and vaccines for prevention of diseases for which no vaccines exist. Furthermore, fully new applications to prevention or treatment of chronic diseases not traditionally associated with infections are expected.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640596     DOI: 10.1111/j.1574-6976.2000.tb00530.x

Source DB:  PubMed          Journal:  FEMS Microbiol Rev        ISSN: 0168-6445            Impact factor:   16.408


  9 in total

1.  The molecular biologist against infectious disease. Infectious diseases, in both the developing and the developed world, still pose considerable challenges to biomedical research. But science alone is clearly not sufficient to overcome the burden of disease in the world.

Authors:  P Helena Mäkelä
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

2.  Materials that harness and modulate the immune system.

Authors:  Jamal S Lewis; Krishnendu Roy; Benjamin G Keselowsky
Journal:  MRS Bull       Date:  2014-01-01       Impact factor: 6.578

3.  Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis.

Authors:  David N Harland; Karen Chu; Ashraful Haque; Michelle Nelson; Nicola J Walker; Mitali Sarkar-Tyson; Timothy P Atkins; Benjamin Moore; Katherine A Brown; Gregory Bancroft; Richard W Titball; Helen S Atkins
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

Review 4.  Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.

Authors:  Maria-Cristina S Pranchevicius; Thiessa R Vieira
Journal:  Bioengineered       Date:  2013-04-22       Impact factor: 3.269

5.  Meningococcal PorB induces a robust and diverse antigen specific T cell response as a vaccine adjuvant.

Authors:  Munir Mosaheb; Lee M Wetzler
Journal:  Vaccine       Date:  2018-10-28       Impact factor: 3.641

6.  A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against Bordetella pertussis, Including Pertactin Deficient Strains.

Authors:  María Eugenia Zurita; Mieszko M Wilk; Francisco Carriquiriborde; Erika Bartel; Griselda Moreno; Alicja Misiak; Kingston H G Mills; Daniela Hozbor
Journal:  Front Cell Infect Microbiol       Date:  2019-04-26       Impact factor: 5.293

7.  Developing Phytocompounds from Medicinal Plants as Immunomodulators.

Authors:  Chih-Chun Wen; Hui-Ming Chen; Ning-Sun Yang
Journal:  Adv Bot Res       Date:  2012-06-19       Impact factor: 2.175

Review 8.  Production of virus-like particles for vaccines.

Authors:  J Fuenmayor; F Gòdia; L Cervera
Journal:  N Biotechnol       Date:  2017-08-01       Impact factor: 5.079

9.  The histo-blood group antigens of the host cell may determine the binding of different viruses such as SARS-CoV-2.

Authors:  Mayra Cuéllar-Cruz
Journal:  Future Microbiol       Date:  2021-01-18       Impact factor: 3.165

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.